SGLT2 inhibitors in heart failure

CPD
By
AP Staff
-

References 

  1. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. 
  2. Atherton J, Sindone A, De Pasquale CG et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung Circ 2018;27:1123–208. 
  3. Health AIo, Welfare. Heart, stroke and vascular disease: Australian facts. Canberra: AIHW; 2024. At: www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/about 
  4. Sall F, Adoubi A, Boka C, et al. Post discharge management of heart failure patients: clinical findings at the first medical visit in a single-center study. BMC Cardiovasc Disord 2023;23(1):94. 
  5. Bytyçi I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol 2015;15(1):63–8. 
  6. Overview of heart failure. Therapeutic guidelines; [updated 2023 June]. At: https://app.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=heart-failure&guidelinename=Cardiovascular&sectionId=toc_d1e47#toc_d1e47 
  7. Sindone AP, De Pasquale C, Amerena J et al. Consensus statement on the current pharmacological prevention and management of heart failure. Med J Aust 2022;217(4):212–17. 
  8. Gevaert AB, Boen JRA, Segers VF et al. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol 2019;10:638. 
  9. Rossi S, ed. Heart failure. Australian medicines handbook; [updated 2024 July]. At: https://amhonline.amh.net.au/chapters/cardiovascular-drugs/drugs-heart-failure/heart-failure 
  10. Heart failure with reduced ejection fraction (HFrEF). Therapeutic guidelines; [updated 2024 Dec]. At: https://app.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=heart-failure&guidelinename=Cardiovascular&sectionId=toc_d1e402#toc_d1e402 
  11. Heart Failure Society of America. Managing Heart Failure. 2023. At: https://hfsa.org/managing-heart-failure 
  12. Tromp J, Ouwerkerk W, Van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. Journal of the American College of Cardiology: Heart Failure 2022;10(2):73–84.
  13. Bassi NS, Ziaeian B, Yancy CW et al. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol 2020;5(8):948–51. 
  14. Heart failure with mildly reduced ejection fraction (HFmrEF). Therapeutic guidelines; [updated 2024 Dec]. At: https://app.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=cardiovascular-disease-risk-stratification&guidelinename=auto&sectionId=c_CVG_Heart-failure-with-mildly-reduced-ejection-fractiontopic_2#c_CVG_Heart-failure-with-mildly-reduced-ejection-fractiontopic_2 
  15. McDonagh T, Metra M, Adamo M et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2023;44:3627–39. 
  16. Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451–61. 
  17. Heart failure with preserved ejection fraction (HFmrEF). Therapeutic guidelines; [updated 2024 Dec]. At: https://app.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=cardiovascular-disease-risk-stratification&guidelinename=auto&sectionId=c_CVG_Heart-failure-with-preserved-ejection-fractiontopic_2#c_CVG_Heart-failure-with-preserved-ejection-fractiontopic_2 
  18. Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387(12):1089–98. 
  19. Pitt B, Pfeffer MA, Assmann SF et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370(15):1383–92. 
  20. Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care 2018;41(1):14–31. 
  21. Paul A, Tabaja C, Wazbi O. SGLT2 inhibitors and the cardiac rhythm: unraveling the connections. Int J Arrhythmia 2024;25(1):2. 
  22. Severino P, D’Amato A, Prosperi S, et al. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Fail Rev 2023;28(3):709–21. 
  23. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 2020;43(3):508–11. 
  24. Rossi S, ed. Sodium-glucose co-transporter 2 inhibitors. Australian medicines handbook; [updated 2024 July]. At: https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-diabetes/sodium-glucose-co-transporter-2-inhibitors 
  25. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117–28. 
  26. Group TE-KC. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388(2):117–27. 
  27. Umanath K, Testani JM, Lewis JB. “Dip” in eGFR: Stay the course with SGLT-2 inhibition. Circulation 2022;146(6):463–5. 
  28. Heerspink HJL. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383(15):1436-46. 
  29. McMurray J, Solomon S, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381(21):1995–2008. 
  30. Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383(15):1413–24. 
  31. Rossi S, ed. Dapagliflozin. Australian medicines handbook; [updated 2024 July]. At: https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-diabetes/sodium-glucose-co-transporter-2-inhibitors/dapagliflozin 
  32. Rossi S, ed. Empagliflozin. Australian medicines handbook; [updated 2024 July]. At: https://amhonline.amh.net.au/chapters/endocrine-drugs/drugs-diabetes/sodium-glucose-co-transporter-2-inhibitors/empagliflozin 
  33. DeSantis, A. Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycaemia in type 2 diabetes mellitus. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA [internet]. At: www.uptodate.com 
  34. Heerspink HJL, Cherney DZI. Clinical Implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol 2021;16(8):1278–80. 
  35. Queensland Health. Sodium-glucose co-transporter-2 (SGLT2) inhibitors for heart failure: patient information. 2022. At: https://www.health.qld.gov.au/__data/assets/pdf_file/0022/1154380/SGLT2-inhibitor-Patient-Information.pdf 
  36. Country Health SA Diabetes Service. SGLT2 Inhibitors – Medication for type 2 diabetes: consumer information. 2020. At: https://www.chsa-diabetes.org.au/consumer/Medication_SGLT2_FINAL_May%2020.pdf 
  37. Jaarsma T, Hill L, Bayes-Genis A et al. Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021 Jan;23(1):157–174. 
  38. Heart Foundation. Managing symptoms: Management of fluid status changes. 2025. At: www.heartonline.org.au/articles/treatment-management/managing-symptoms#management-fluid-status-changes